Llwytho...
Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon EGFR mutations: a case report and literature review
BACKGROUND: Osimertinib is the standard of care for patients with non-small-cell lung cancer (NSCLC) patients harboring acquired EGFR T790M resistance mutation. However, the frequency of T790M resistance mutation acquisition and the efficacy of osimertinib in patients harboring uncommon EGFR mutatio...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Onco Targets Ther |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove Medical Press
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6348971/ https://ncbi.nlm.nih.gov/pubmed/30774361 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S190034 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|